Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
Sign Up to like & getrecommendations! Published in 2022 at "ESMO Open"
DOI: 10.1016/j.esmoop.2022.100455
Abstract: Background Chemoradiotherapy with durvalumab consolidation has yielded excellent results in stage III non-small-cell lung cancer (NSCLC). Therefore, it is essential to identify patients who might benefit from a surgical approach. Material and methods Data from… read more here.
Keywords: stage iii; operable stage; sakk; sakk sakk ... See more keywords
Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Cancer"
DOI: 10.1038/s41416-020-01073-3
Abstract: Treatment decisions with curative intent for patients with stage III non-small cell lung cancer (NSCLC) often require a complex decision process, and benefit from continuous communication of expertise among, and between, lung cancer teams. In… read more here.
Keywords: stage iii; treatment; iii nsclc; cancer ... See more keywords
Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2023.2179479
Abstract: ABSTRACT Introduction The growing body of real-life data on maintenance treatment with durvalumab suggests that immunological markers of the cancer host interplay may have significant effects on the efficacy of multimodal therapy in patients with… read more here.
Keywords: five years; iii nsclc; stage iii; treatment ... See more keywords
279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0279
Abstract: Background Chemoradiotherapy (CRT) followed by maintenance treatment with the PD-L1 inhibitor durvalumab is a new standard of care for inoperable stage III NSCLC. The present study aims to evaluate the oncological outcome of patients treated… read more here.
Keywords: stage iii; iii nsclc; crt; inoperable stage ... See more keywords
Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221113268
Abstract: Consolidation anti-programmed death-ligand 1 has become a new standard of care in unresectable stage III non-small cell lung cancer (NSCLC) following chemo-radiotherapy (CTRT), based on the results of two phase III trials. Advances remain however… read more here.
Keywords: iii nsclc; unresectable stage; stage iii; current challenges ... See more keywords
Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221116605
Abstract: Introduction: Despite radical intent therapy for patients with stage III non-small-cell lung cancer (NSCLC), cumulative incidence of brain metastases (BM) reaches 30%. Current risk stratification methods fail to accurately identify these patients. As radiomics features… read more here.
Keywords: development; iii nsclc; stage iii; radically treated ... See more keywords
The efficacy and safety of induction chemoradiotherapy (ICRT) followed by surgery in stage III NSCLC patients (pts) with T3/4-adjacent organ invasion involved(AOI): A single-center retrospective observational study.
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2018.pa2223
Abstract: Background: The 2-year overall survival (OS) of c-Stage IIIA/B non-small cell lung cancer (NSCLC) is each 53% and 34% in IASLC Staging Project (7th) and the treatments remain controversial. Especially, multimodal treatment at stage III… read more here.
Keywords: retrospective observational; observational study; stage iii; iii nsclc ... See more keywords
Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.9010
Abstract: 9010Background: Consolidation PD-1/PD-L1 inhibition after chemoradiation (CRT) for unresectable stage III NSCLC improves overall survival. In stage IV NSCLC, the combination of nivolumab/ipilimumab... read more here.
Keywords: consolidation; stage iii; unresectable stage; iii nsclc ... See more keywords
Longitudinal analysis of dynamic changes of T-lymphocytes during multimodal treatment of patients with inoperable stage III NSCLC.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e20503
Abstract: e20503 Background: Acute lymphocytopenia is associated with poor survival in solid cancers treated with multimodal therapy. A prospective analysis of peripheral blood mononuclear cells (PBMCs) during multimodal treatment in inoperable stage III NSCLC patients was… read more here.
Keywords: cd3; stage iii; treatment; multimodal treatment ... See more keywords
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
Sign Up to like & getrecommendations! Published in 2021 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s305466
Abstract: Abstract Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non–small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown… read more here.
Keywords: nsclc durvalumab; stage iii; durvalumab; iii nsclc ... See more keywords
Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.984932
Abstract: Background Thermal ablation (TA) is considered a safe alternative to surgical resection for the treatment of non-small cell lung cancer (NSCLC). While previous studies have shown that TA is beneficial for stage I NSCLC patients,… read more here.
Keywords: iii nsclc; ablation; stage iii; patients stage ... See more keywords